Development of initial loading procedure for teicoplanin in critically Ill patients with severe infections

Kazuaki Matsumoto, Naoko Kanazawa, Erika Watanabe, Yuta Yokoyama, Tomohide Fukamizu, Yoshihiro Shimodozono, Chiharu Maeda, Tomotsugu Yasuda, Yasuyuki Kakihana, Kazuro Ikawa, Norifumi Morikawa, Yasuo Takeda

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is now endemic in many hospitals. Infection with MRSA is more frequent in the intensive care unit (ICU) than in general wards. Therefore, appropriate treatments for MRSA infections will lead to good outcomes in the ICU. Teicoplanin is an anti-MRSA agent. Recently, it was recommended at a new target trough concentration of 15-30 μg/mL. However, the initial loading procedure for teicoplanin to allow it to reach the target concentration promptly remains uncertain. Therefore, this study aimed to determine the appropriate initial loading procedure for teicoplanin in critically ill patients with severe infections. We performed a retrospective study in patients given teicoplanin in the ICU in order to determine the initial loading procedure to promptly reach the target trough concentration. We then evaluated the trough concentration on the third day after commencement of teicoplanin therapy. The mean loading dose and trough concentration were 11.5±1.0 mg/kg and 18.9±5.9 μg/mL, respectively. A correlation (r=0.45, p=0.046) was shown between teicoplanin loading dose and trough concentration. The correlation equation was trough concentration=2. 563·loading dose -10.672. In the cases of 11.0 and 15.0 mg/kg for the loading dose, respectively, trough concentrations were 17.5 and 27.8 μg/mL. We suggested that an initial loading dose of 11-15 mg/kg every 12 h for 3 doses should be administered to promptly achieve the target trough concentration of 15-30 μg/mL on the third day after commencement of teicoplanin therapy in the ICU.

Original languageEnglish
Pages (from-to)1024-1026
Number of pages3
JournalBiological and Pharmaceutical Bulletin
Volume36
Issue number6
DOIs
Publication statusPublished - 2013 Jun
Externally publishedYes

Fingerprint

Teicoplanin
Critical Illness
Methicillin-Resistant Staphylococcus aureus
Infection
Intensive Care Units
Patients' Rooms
Therapeutics
Retrospective Studies

Keywords

  • Loading dose
  • Methicillin-resistant Staphylococcus aureus
  • Teicoplanin
  • Trough concentration

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

Development of initial loading procedure for teicoplanin in critically Ill patients with severe infections. / Matsumoto, Kazuaki; Kanazawa, Naoko; Watanabe, Erika; Yokoyama, Yuta; Fukamizu, Tomohide; Shimodozono, Yoshihiro; Maeda, Chiharu; Yasuda, Tomotsugu; Kakihana, Yasuyuki; Ikawa, Kazuro; Morikawa, Norifumi; Takeda, Yasuo.

In: Biological and Pharmaceutical Bulletin, Vol. 36, No. 6, 06.2013, p. 1024-1026.

Research output: Contribution to journalArticle

Matsumoto, K, Kanazawa, N, Watanabe, E, Yokoyama, Y, Fukamizu, T, Shimodozono, Y, Maeda, C, Yasuda, T, Kakihana, Y, Ikawa, K, Morikawa, N & Takeda, Y 2013, 'Development of initial loading procedure for teicoplanin in critically Ill patients with severe infections', Biological and Pharmaceutical Bulletin, vol. 36, no. 6, pp. 1024-1026. https://doi.org/10.1248/bpb.b12-00911
Matsumoto, Kazuaki ; Kanazawa, Naoko ; Watanabe, Erika ; Yokoyama, Yuta ; Fukamizu, Tomohide ; Shimodozono, Yoshihiro ; Maeda, Chiharu ; Yasuda, Tomotsugu ; Kakihana, Yasuyuki ; Ikawa, Kazuro ; Morikawa, Norifumi ; Takeda, Yasuo. / Development of initial loading procedure for teicoplanin in critically Ill patients with severe infections. In: Biological and Pharmaceutical Bulletin. 2013 ; Vol. 36, No. 6. pp. 1024-1026.
@article{1fcb166d7a9149ea87eb1ce27bc1188d,
title = "Development of initial loading procedure for teicoplanin in critically Ill patients with severe infections",
abstract = "Methicillin-resistant Staphylococcus aureus (MRSA) is now endemic in many hospitals. Infection with MRSA is more frequent in the intensive care unit (ICU) than in general wards. Therefore, appropriate treatments for MRSA infections will lead to good outcomes in the ICU. Teicoplanin is an anti-MRSA agent. Recently, it was recommended at a new target trough concentration of 15-30 μg/mL. However, the initial loading procedure for teicoplanin to allow it to reach the target concentration promptly remains uncertain. Therefore, this study aimed to determine the appropriate initial loading procedure for teicoplanin in critically ill patients with severe infections. We performed a retrospective study in patients given teicoplanin in the ICU in order to determine the initial loading procedure to promptly reach the target trough concentration. We then evaluated the trough concentration on the third day after commencement of teicoplanin therapy. The mean loading dose and trough concentration were 11.5±1.0 mg/kg and 18.9±5.9 μg/mL, respectively. A correlation (r=0.45, p=0.046) was shown between teicoplanin loading dose and trough concentration. The correlation equation was trough concentration=2. 563·loading dose -10.672. In the cases of 11.0 and 15.0 mg/kg for the loading dose, respectively, trough concentrations were 17.5 and 27.8 μg/mL. We suggested that an initial loading dose of 11-15 mg/kg every 12 h for 3 doses should be administered to promptly achieve the target trough concentration of 15-30 μg/mL on the third day after commencement of teicoplanin therapy in the ICU.",
keywords = "Loading dose, Methicillin-resistant Staphylococcus aureus, Teicoplanin, Trough concentration",
author = "Kazuaki Matsumoto and Naoko Kanazawa and Erika Watanabe and Yuta Yokoyama and Tomohide Fukamizu and Yoshihiro Shimodozono and Chiharu Maeda and Tomotsugu Yasuda and Yasuyuki Kakihana and Kazuro Ikawa and Norifumi Morikawa and Yasuo Takeda",
year = "2013",
month = "6",
doi = "10.1248/bpb.b12-00911",
language = "English",
volume = "36",
pages = "1024--1026",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "6",

}

TY - JOUR

T1 - Development of initial loading procedure for teicoplanin in critically Ill patients with severe infections

AU - Matsumoto, Kazuaki

AU - Kanazawa, Naoko

AU - Watanabe, Erika

AU - Yokoyama, Yuta

AU - Fukamizu, Tomohide

AU - Shimodozono, Yoshihiro

AU - Maeda, Chiharu

AU - Yasuda, Tomotsugu

AU - Kakihana, Yasuyuki

AU - Ikawa, Kazuro

AU - Morikawa, Norifumi

AU - Takeda, Yasuo

PY - 2013/6

Y1 - 2013/6

N2 - Methicillin-resistant Staphylococcus aureus (MRSA) is now endemic in many hospitals. Infection with MRSA is more frequent in the intensive care unit (ICU) than in general wards. Therefore, appropriate treatments for MRSA infections will lead to good outcomes in the ICU. Teicoplanin is an anti-MRSA agent. Recently, it was recommended at a new target trough concentration of 15-30 μg/mL. However, the initial loading procedure for teicoplanin to allow it to reach the target concentration promptly remains uncertain. Therefore, this study aimed to determine the appropriate initial loading procedure for teicoplanin in critically ill patients with severe infections. We performed a retrospective study in patients given teicoplanin in the ICU in order to determine the initial loading procedure to promptly reach the target trough concentration. We then evaluated the trough concentration on the third day after commencement of teicoplanin therapy. The mean loading dose and trough concentration were 11.5±1.0 mg/kg and 18.9±5.9 μg/mL, respectively. A correlation (r=0.45, p=0.046) was shown between teicoplanin loading dose and trough concentration. The correlation equation was trough concentration=2. 563·loading dose -10.672. In the cases of 11.0 and 15.0 mg/kg for the loading dose, respectively, trough concentrations were 17.5 and 27.8 μg/mL. We suggested that an initial loading dose of 11-15 mg/kg every 12 h for 3 doses should be administered to promptly achieve the target trough concentration of 15-30 μg/mL on the third day after commencement of teicoplanin therapy in the ICU.

AB - Methicillin-resistant Staphylococcus aureus (MRSA) is now endemic in many hospitals. Infection with MRSA is more frequent in the intensive care unit (ICU) than in general wards. Therefore, appropriate treatments for MRSA infections will lead to good outcomes in the ICU. Teicoplanin is an anti-MRSA agent. Recently, it was recommended at a new target trough concentration of 15-30 μg/mL. However, the initial loading procedure for teicoplanin to allow it to reach the target concentration promptly remains uncertain. Therefore, this study aimed to determine the appropriate initial loading procedure for teicoplanin in critically ill patients with severe infections. We performed a retrospective study in patients given teicoplanin in the ICU in order to determine the initial loading procedure to promptly reach the target trough concentration. We then evaluated the trough concentration on the third day after commencement of teicoplanin therapy. The mean loading dose and trough concentration were 11.5±1.0 mg/kg and 18.9±5.9 μg/mL, respectively. A correlation (r=0.45, p=0.046) was shown between teicoplanin loading dose and trough concentration. The correlation equation was trough concentration=2. 563·loading dose -10.672. In the cases of 11.0 and 15.0 mg/kg for the loading dose, respectively, trough concentrations were 17.5 and 27.8 μg/mL. We suggested that an initial loading dose of 11-15 mg/kg every 12 h for 3 doses should be administered to promptly achieve the target trough concentration of 15-30 μg/mL on the third day after commencement of teicoplanin therapy in the ICU.

KW - Loading dose

KW - Methicillin-resistant Staphylococcus aureus

KW - Teicoplanin

KW - Trough concentration

UR - http://www.scopus.com/inward/record.url?scp=84878867489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878867489&partnerID=8YFLogxK

U2 - 10.1248/bpb.b12-00911

DO - 10.1248/bpb.b12-00911

M3 - Article

VL - 36

SP - 1024

EP - 1026

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 6

ER -